Method for oxidative stress correction in preventing and treating iron-deficiency anaemia in calves exposed to chronic incorporated radiation
SUBSTANCE: invention refers to veterinary science, namely to clinical pharmacology and veterinary therapy. The method consists in administering the complex iron-dextran preparation Ferranimal-75M intramuscularly on the 5th day of calf's life in a dose of 3 ml in a combination with an intramuscular injection of the preparation Hydropeptone in a dose of 10 ml. Ferranimal-75M is injected 10 days later in a dose of 2 ml in a combination with an injection of Hyropeptone 5 ml intramuscularly in different points.
EFFECT: method provides higher antioxidative activity of calf's blood serum, reduced pro-oxidant action of iron and incorporated radionuclides, as well as higher iron accessibility in treating and preventing iron-deficiency anaemia in calves exposed to the chronic incorporated radiation.
The invention relates to the field of veterinary medicine, namely clinical pharmacology and therapy animals, relates to a method for the treatment and prevention of diseases of animals caused by a deficiency in their body iron, and correction side effects of iron supplements.
Iron plays an important role in the life of humans and animals. Change its contents can lead to various pathological conditions: iron deficiency develops iron deficiency anemia, whereas the excess of it causes hemochromatosis and hemosiderosis with severe lesions of various organs and systems. Causes of iron deficiency anaemia varied. It can be: "poverty" iron depot when insufficient the flow of food; increased the body's need for iron; inadequate absorption of iron in the gastrointestinal tract; excessive loss of iron by the body and other reasons. It is also known that in animals under conditions of constant incorporated exposure (ingestion of radionuclides in the body of the animal with food, dwelling in areas contaminated with radionuclides), there is a significant decrease in the concentration of iron in proteins of the bone marrow, resulting in impaired synthesis of hemoglobin and, therefore, reduced hemoglobin content in erythrocytes, at the same time, what about the decrease in the number of erythrocytes, that leads to the development of nutritional (iron deficiency) anemia .
For the treatment and prevention of nutritional anaemia in farm animals using iron supplements. Known drug usage Farmanimal-75 (synonym of Feroglobin-75), a colloidal solution of a complex of ferric hydroxide with low molecular weight dextran in water, for the prevention and treatment of iron deficiency anemia in all species of farm animals and fur-bearing animals . The disadvantage of this drug before the drug, the proposed method is the absence in the composition of the trace elements copper and cobalt, contributing to increased absorption of iron, and also stimulating haematopoiesis, and the lack of selenium has antioxidant properties.
The prior art method of correction of antioxidant activity of the liquid portion of the blood of newborn calves with iron deficiency anemia, including the use of a solution Feroglobin-75 intramuscularly once daily in combination with oral application of glicerina . The disadvantage of this method, selected as a prototype, is its application only to new-born calves with already developed anemia, which does not allow to use this method on other age groups of calves and to use this method to prevent anemia, and t is the train this method does not take into account prooxidant properties of iron, part of the preparation. In the proposed method, the correction is possible in the prevention and treatment of anemia, and applicable on the calves of different age groups (newborn calves, calves suckling period). In addition, our proposed method of correction of oxidative stress refers to animals under chronic incorporated irradiation.
One of the disadvantage of this method is the lack of essential amino acids contained in the hydrolyzate of soybean protein used in the inventive method.
The technical result of the claimed invention is to increase the antioxidant activity of the blood serum of calves, reduced prooxidant action of iron and of incorporated radionuclides, as well as increasing the absorption of iron in the treatment and prevention of iron deficiency anemia in chronic conditions incorporated irradiation.
The objective of the invention is to provide a method for correcting the level of antioxidant activity of blood serum and of lipid peroxidation in the prevention and treatment of iron deficiency anemia calves in conditions of chronic incorporated irradiation.
For the correction of oxidative stress in the prevention and treatment of iron deficiency anemia calves in conditions of chronic incorporando what about the radiation used drug Farmanimal-75M (active ingredients: iron (III) 75 mg dextranomer complex, 0.10 mg of copper (II) in dextranomer complex, 0.20 mg of cobalt (II) in dextranomer complex, 0.05 mg selenium(IV) stable ) in combination with Hydropeptide - hydrolyzed soy protein compensated for methionine in the form of solution for injection use, which contains all the essential amino acids and lower peptides. The simultaneous appointment of protein hydrolysate stimulates velocimeters function of the body, promote the absorption of trace elements entering into the composition of the drug Farmanimal-75M, while reducing their prooxidant actions and increase antioxidant activity in the blood serum. It is also possible supplemental vitamin B1 in the dose of 2.5 mg and vitamin PP in a dose of 3.7 mg
This technical result is achieved in the following way. To increase the antioxidant activity of blood serum, lower level of lipid peroxidation and increase the absorption of iron appoint injected intramuscularly on days 3-5 of life drug Farmanimal-75M dose of 3 ml, and then repeat injection after 10 days at a dose of 2 ml, simultaneously with the first injection Farmanimal-75M intramuscularly in another place impose drug Hydropath in the dose of 10 ml simultaneously with the second injection Farmanimal-75M, also intramuscularly in another place impose drug Hydropath at a dose of 5 ml
The method is as follows. The calf in the appointment injected intramuscularly on days 3-5 of life zhelezobaktery drug Farmanimal-75M dose of 3 ml, and then repeat injection after 10 days at a dose of 2 ml, simultaneously with the first injection Farmanimal-75M, intramuscularly in another place impose drug Hydropath in the dose of 10 ml, representing a protein hydrolysate compensated for methionine, simultaneously with the second injection Farmanimal-75M, also intramuscularly in another place impose drug Hydropath at a dose of 5 ml
As a result of application of this method found that when radiation absorbed dose for internal radiation, equal to 12-18 mGy/year137Cs, on the 15th and 25th day of life calves significantly increased level of antioxidant activity of blood serum, and decreased the number of primary products of lipid peroxidation. So the number of diene conjugates on the 15th 0.6% opt.PL/ml and in the control of 1.1% opt.PL/ml, on the 25th day, the number of diene conjugates constituted 0.7% of the protected area.PL/ml and in the control of 1.3% opt.PL/ml Number tranovich conjugates on the 15th was 0.3% opt.PL/ml and in the control of 0.8% opt.PL/ml, on the 25th day, the number tranovich conjugates amounted to 0.4% of the protected area.PL/ml and in the control of 0.9% opt.PL/ml Number oxadiazole conjugates on the 15th 0.5% opt.PL/ml and in the control of 1.1% on the so PL/ml, on the 25th day, the number oxadiazole conjugates was 0.5% opt.PL/ml and in the control of 1.0% of the protected area.PL/ml Number of Schiff bases on the 15th 0.5% opt.PL/ml and in the control of 1.3% opt.PL/ml, on the 25th day, the number of Schiff bases amounted to 0.6% of the protected area.PL/ml and in the control of 1,4 units of the Park.PL/ml Level of antioxidant activity on the 15th day life in the blood serum of calves from the experimental group amounted to 18.0±1,2%, while in the control group calves level of antioxidant activity was significantly lower and amounted to 13.6±0.9 per cent. After the second injection the level of antioxidant activity continued to increase and amounted in the experimental group and 24.6±3.6%, and in the control of 15.3±1,1%.
As can be seen from the presented data, in animals treated according to the proposed method in comparison with control, significantly higher level of antioxidant activity of blood serum and below the level of the primary products of peroxidation, indicating a high activity of the claimed method for use in the treatment and prevention of iron deficiency anemia in chronic conditions incorporated irradiation.
The use of the proposed method of correction of the level of antioxidant activity of blood serum and of lipid peroxidation in the prevention and treatment of iron deficiency anemia calves in conditions of chronic inkorporira the aqueous exposure will help to avoid the negative effects of ferreteria and reduce the impact of chronic incorporated irradiation, interferes with normal absorption of iron and contributing peroxide oxidation of lipids, which increases the health, productivity and growth of animals, renders prophylactic action onset of the disease and reduces recovery time.
1. A. N. Urazaev, A. A. Dealers, L. P., Parasyuk, R. D. Urazayeva. The biological role of iron. The use of iron preparations in veterinary medicine: a monograph. - M.: Kolos, 2010, - 17 S., 41 C., 50 C.).
2. Found on the Internet: http://webmvc.com/vet/leki/17/abio/ferran.php.
3. The patent RU 246910 C1, publ. 20.12.2012.
4. Found on the Internet: http://www.vetlek.ru/directions/7icH646.
The correction method of oxidative stress in the prevention and treatment of iron deficiency anemia calves in conditions of chronic incorporated irradiation, including the introduction of a comprehensive geisterstreiber drug Farmanimal-75M, intramuscularly, on the 5th day of life of the calf, at a dose of 3 ml, along with intramuscular injection of the drug Hydropath in the dose of 10 ml, and the injection Farmanimal-75M repeated after 10 days at a dose of 2 ml, simultaneously with the injection of 5 ml of Hydropeptide, intramuscularly in different places.
FIELD: veterinary medicine.
SUBSTANCE: ferroglyukin is administered to new-born calves with iron deficiency anaemia at a dose of 150 mg (2 ml) intramuscularly, twice with an interval of 4 days. Crezacyne 5 mg/kg per day is included in the watering scheme for 4 days, starting simultaneously with the first injection of ferroglyukin. Gamavit is administered intramuscularly once a day in the morning at a dose of 0.05 ml/kg for 4 days, starting simultaneously with ferroglyukin and crezacyne.
EFFECT: method enables to normalise consistently the platelet activity in new-born calves with iron deficiency anaemia during a short period of exposure, transferring it to the level typical of healthy calves, after 4 days of treatment, and to provide long-term maintenance of platelet haemostasis in the optimal mode of operation, eliminating the risk of thrombotic complications in animals and contributing to their normal growth and development.
SUBSTANCE: invention relates to casein succinylate of iron (III) wherein iron content varies from 4.5 wt % to 7 wt %, water solubility exceeds 92% while phosphorus-to-nitrogen ratio exceeds 5 wt %.
EFFECT: additionally, invention relates to production of iron (III) and to pharmaceutical composition containing casein succinylate of iron (III).
17 cl, 4 tbl, 9 ex
SUBSTANCE: invention relates to the field of organic chemistry, namely to benzoimidazole derivatives of formula (I), as well as to their enantiomers, diastereoisomers, racemates and pharmaceutically acceptable salts, where n equals from 2 to 4, each of R1 substituents is independently selected from H, halogen, -C1-4alkyl, -C1-4pergaloalkyl, trifluoro-C1-4alkoxy, -NO2, -CN, CO2H, -OC1-4alkyl, -SC1-4alkyl, -S(C1-4alkyl)-Rc, -S(O)2(C1-4alkyl)-Rc, -S(O)-C1-4alkyl, -SO2-C1-4alkyl, -S-Rc, -S(O)-Rc, -SO2-Rc, -SO2-NH-Rc, -O-Rc, -CH2-O-Rc, -C(O)NH-Rc, -NRaRb, benzyloxy, phenyl, optionally substituted with one-two Rd, cyanobiphenyl-4-ylmethylsulpfanyl, cyanobiphenyl-4-ylmethanesulphonyl, or -S-(CH2)2-morpholine and two adjacent groups R1 can bind with formation of an aromatic 5-6-membered ring, optionally substituted with one methyl group or two atoms of halogen, optionally containing one or two S or N; Ra and Rb each independently represents C1-4alkyl, -C(O)C1-4alkyl, -C(O)-Rc, -C(O)CH2-Re, C1-4alkyl-Re, -SO2-Rc, -SO2-C1-4alkyl, phenyl, benzyl; or Ra and Rb together with a nitrogen atom, which they are bound with, form a monocyclic 5-6- membered heterocycloalkyl ring, optionally containing one heteroatom, selected from O; Rc represents -C3-8cycloalkyl, phenyl, optionally substituted with one-two Rd, benzyl, optionally substituted with one-three Rd; morpholine; Rd independently represents halogen, -OH, -C1-4alkyl or -C1-4perhalogenalkyl, trifluorine C1-4alcoxy, -OC1-4alkyl, or -O-benzyl optionally substituted with halogen, Re represents -C6heterocycloalkyl, optionally containing one or two of O or N atoms, optionally substituted with a methyl group; R2 and R3 both represent H, -CF3 or C1-3alkyl; each of Z represents a C or N atom, on condition that simultaneously not more than two Z represent N. The invention also relates to particular compounds, a pharmaceutical composition, based on formula (I) compound or a particular said compound, a method of treating diseases, mediated by propyl hydroxylase activity.
EFFECT: novel derivatives of benzimidazole, possessing an inhibiting activity with respect to PHD are obtained.
11 cl, 1 tbl, 186 ex
SUBSTANCE: in a compound of formula ,
X means N or CH, R1 means hydrogen or cyano, R2 means saturated 4-7-membered residue of heterocyclyl, which is bound through a nitrogen atom that contains 1 to 2 heteroatoms chosen from N and O. Besides, heterocyclyl residue can be replaced with one substituent chosen from a group consisting of C3-C6-cycloalkyl, or with 1-4 fluorine atoms. The invention also refers to a method for obtaining compounds and to a medicine on their basis.
EFFECT: compounds can be used for production of a medicine suitable for being used in a method of treatment or prophylaxis of cardiovascular diseases, cardiac insufficiency, anemia, chronic diseases of kidneys and kidney failure.
16 cl, 1 tbl, 29 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and aims at the simultaneous control of coccidiosis and iron deficiency. The compound comprises triazinones of formulas (I) or (II) wherein R1 means CF3-SO2- or CF3-S-, R2 means CH3, each R4, R5 and R6 means Cl (chlorine) or pharmaceutically acceptable salts thereof, and iron compounds (3+) specified in a group consisting of: multinucleated complex iron (III) and polysaccharide compounds and ammonium-iron (III) citrate. What is also declared is using the above compounds for producing drug preparations.
EFFECT: using the declared group of inventions is effective for the simultaneous control of coccidiosis and iron deficiency; it is accompanied by no adverse phenomena; the compound ingredients have no negative effects on each other; and their biological activity preserves.
17 cl, 15 tbl, 7 ex
SUBSTANCE: invention relates to production of peptide derivative mimetic of EPO, with the formula: R1-R2-(CH2)n1-R3-(CH2)n2-R4-R5 (I) and its pharmaceutical salts, where R1, R5 are selected from cyclic peptides with sequences SEQ ID NO:5, 6, 7 and 8; n1, n2 represent integer numbers independently selected from 0-10; R2, R4 are selected from -CO or -CH2; R3 is selected from O, S, CH2, N(CH2)n3NHR6, NCO(CH2)n4NHR6, CHOCONH(CH2)n5NHR6, CHSCON(CH2)n5NHR6 or CHNHCON(CH2)n5NHR6; where n3 represents an integer number selected from 1-10, n4 is an integer number selected from 2-10, n5 represents an integer number selected from 2-10, R6 is selected from H or derivatives of metoxyethylene glycol. The produced peptide or its pharmaceutically acceptable salt is used within a pharmaceutical composition for treatment of disorders characterised with EPO deficit, low or defective population of erythrocytes.
EFFECT: invention makes it possible to produce an agonist of EPO receptor having higher biological activity compared to existing EPO mimetics.
15 cl, 2 dwg, 5 tbl, 19 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical industry, and namely to composition for prevention of iron deficiency anemia. Composition for prevention of iron deficiency anemia, which contains source of iron, source of copper, vitamins B1, B3, B6, B9, B12, ascorbic acid, extract from nettle leaves, extract from strawberry leaves, pantohematogen and auxiliary substances, with specified component ratio.
EFFECT: composition makes it possible to extend arsenal of methods for prevention of iron deficiency anemia and is effective.
4 cl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to iron-enriched food product, which contains iron source in form of solid particles, where particles include core, containing iron alginate, and external layer, which contains calcium alginate, where particles are obtained by method which includes the following stages: (i) formation of core, which contains iron alginate, by contact of bioavailable water-soluble salt of iron and one water-soluble alginate salt, (ii) contact of core with water solution of calcium salt, in concentration, which constitutes from 0.025 M to concentration of lower than solution saturation point, and (iii) separation of obtained solid product. Iron-enriched food product is applied for prevention and treatment of iron deficiency conditions of people.
EFFECT: solid particles are applicable for enrichment of food products with iron and is characterised by improved load ability, as well as possesses good stability under standard storage and application conditions.
11 cl, 9 dwg, 13 tbl, 16 ex
SUBSTANCE: invention refers to medicine, namely to cardiology and pulmonology, and concerns treating the patients with chronic obstructive pulmonary disease and ischemic heart disease and cardiac failure complicated by anaemia. For this purpose, pre-treatment haemoglobin and serum iron are evaluated. In that case, if the hemoglobin level is less than 110 mm/l, and the serum iron level is less than 5.85 mmol/l, the conventional treatment involving ACE inhibitors, beta blockers, diuretics, antiaggregants, statins as well as salmeterol and berodual, is added by prescribing an anti-anaemic therapy with Epocrin and Ferrum Lek. Epocrin is administered in a dose of 50 IU/kg subcutaneously 6 times a week; Ferrum Lek is administered in a dose of Fe 100 mg in 5 ml intravenously twice a week. The therapeutic course is 3 months.
EFFECT: this dose schedule of the preparations provides reducing a length of treatment by improving the central haemodynamics, and enhancing the respiratory function.
SUBSTANCE: invention refers to medicine and pharmaceutical industry, and concerns pharmaceutical preparations containing ferric chelate bisglycinate (2) associated with a mixture of sweetening agents with improved flavour.
EFFECT: invention refers to the use if said preparations in prevention and (or) treatment of pathological conditions caused by ferric deficiency.
12 cl, 4 ex
SUBSTANCE: combined therapeutic exposure aiming at increasing an individual's blood melatonin circulation is performed. At 6 p.m., 15-minute Power Plate training is performed. The training follows the regimen: vibrating plate vibration frequency is 30 Hz, one exercise length is 30 sec, the plate shift amplitude is 2 mm, gravity is 1.83 G, pulsed acceleration is 18.00 m/s2. At 6.30 p.m. the patient takes the food stuff 'Samarskiy Zdorovyak' 60g/day to 90g/day, which is prescribed according to the composition depending on the individual's disease. From 7 p.m. to 8 p.m. the patient wears glasses having the function of light radiation within the lenses at a wave length of 480±5 nm to 490±10 nm. The therapeutic sessions are performed once a day from 6.00 p.m. to 8.00 p.m. The length of the course is 1 month three times a year in autumn, winter and spring.
EFFECT: method enables the more effective normalisation of the individual's diurnal rhythm that is ensured by the complex exposure on the humoral and hormonal diurnal variations, functional food stuff, physical load and daylight regulation.
2 cl, 7 tbl, 7 ex
SUBSTANCE: invention refers to medicine, namely to functional diagnostics, and can be used in assessing the blood microcirculation status in a patient's limbs by determining a relation between the blood flows in the paired organs or paired regions of interest by radionuclide diagnostics. That is ensured by inserting a microcatheter with a two-way cock and two syringes attached, into the ulnar or other forearm vein. One syringe contains an indicator, an amount of which shall not exceed 0.3-0.5 ml, while the other syringe contains normal saline. Immediately after the indicator is introduced into the catheter, it is pushed on by normal saline from the second syringe. A camera is used to record gamma emission and a radioactivity-time curve is constructed. The radioactivity-time curves are rated by an area of the specified regions of interest y1(t)/S1, y2(t)/S2 to construct the initial radioactivity-time curves y1(t), y2(t), which are approximated by orthogonal polynominals α1(t), α2(t) in the form of a parametric curve ψ[α1(t), α2(t)], whereon a straight-line segment is specified between the points t1 and t2 for the following approximation implemented by the least square method and represented by the straight line y=kx+b. Herewith, y is an approximated radioactivity in the 1st region of interest , x is an approximated radioactivity in the 2nd region of interest, k=tgα, wherein α is an inclination of the straight line to an absciss, b is a segment of the y axis from the coordinate origin to a crossing point of the straight line and the y axis. The required relation D is defined as wherein Q1 is the blood flow (ml/min) in the 1st region of interest, Q2 is the blood flow (ml/min) in the 2nd region of interest.
EFFECT: method provides the timely and accurate diagnosis of limb pathology by determining the blood flow in the region of interest with respect to the examined limb in relation to this value in the contralateral limb.
2 cl, 5 dwg, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, pharmacy and pharmacology. What is presented is using 1-(β-phenylethyl)-4-amino-1,2,4-triazolium bromide (Hypertril) as an active base of drug preparations for correcting dysfunctions of the nitroxydergic system of target organs accompanying homocysteinemia and acute cerebrovascular disorders.
EFFECT: what has been shown is achieving the declared application that is normalising the nitroxydergic function irrespective of whether the NO deficiency or hyperproduction is observed; Hypertril is three times more effective to reduce the homocystein production in comparison to the similar known preparation L-arginine, and has no side effect.
2 tbl, 2 ex
SUBSTANCE: halogen-containing hydrocarbonate chloride sodium, alkaline, boron high-magnesium, iodine and fluorine natural mineral water 'Lazarevskaya Tselebnaya' No. 11-M of the Volokonskoye deposit in Sochi is taken according to the following procedure: first course involves administering the water 20-25 minutes before meals in small sips 6 times a day in an amount of 180-200 ml at temperature 23-24°C for 30 days daily with a pause of 1-2 days and repeating the course of administration of the same mineral water 15-20 minutes before meals in small sips 8 times a day in an amount of 150-170 ml at temperature 23-24°C for 30-35 days.
EFFECT: method enables providing higher sportsman's performance by normalising the vegetative nervous system, carbohydrate metabolism values and recovered activity of antioxidant enzymes in erythrocytes.
3 cl, 5 tbl, 2 ex
SUBSTANCE: on the first experimental day, cardiopathy is simulated by a single subcutaneous administration of equally portioned mixture of native egg albumin and Freund's complete adjuvant in rats. The mixture is administered at 0.2 ml of the mixture into 5 injection points: abdominally, into inguinal and axillary regions on the left and right. The cardiopathy is prevented by daily gastric administration of succinic acid 1.5 mmole/kg for 60 days through a probe.
EFFECT: higher clinical effectiveness.
2 dwg, 1 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to medicine and deals with a pharmaceutical composition for stimulation of growth and reproduction of cells in humans and other animals, which contains suitable pharmaceutical fillers and contains polyethyleneglycol-containing conjugate of the human growth hormone prodrug. The group of inventions also relates to a method of obtaining the said conjugate.
EFFECT: group of inventions provides longer activity of rhGH in comparison with non-modified rhGH, which makes it possible to reduce a dose and a mode of introduction, and reduce a level of lipoatrophy.
13 cl, 27 ex, 11 dwg, 2 tbl
SUBSTANCE: complex of biologically active preparations containing glutamic acid, glycine, cysteine, a pectin enterosorbent, a selenium polyvitamin-polymineral complex, a calcium preparation, as well as a cod liver oil preparation rich in nonesterified fatty acids omega 3 is administered. This complex is prescribed as a course of treatment once or twice a year for 4-6 weeks daily in the doses to provide the amounts of glycine of 300 mg, cysteine - 600 mg, glutamic acid - 4 g, selenium - 100 mcg, calcium - 4 g, cod liver oil - 25 ml with 12-15% nonesterified fatty acids omega 3, pectin - 4-5 g, as well as other microelements and vitamins in the doses to fill the normal physiological needs of the body.
EFFECT: lower adverse effects of the general toxic and genotoxic action of nanosilver on the body by normalising lipid peroxidation and the morphofunctional state of the liver and spleen, a lower degree of the DNA fragmentation.
SUBSTANCE: present invention relates to use of enalaprilat, a water-soluble substance based on [L-alanyl]-[L-proline] dipeptide, in medicine. Disclosed is use of enalaprilat as an agent for inhibiting formation of zinc-dependent beta-amyloid dimers.
EFFECT: inhibiting formation of zinc-dependent beta-amyloid dimers.
3 dwg, 1 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to a novel derivative of N-acylanthranilic acid, represented by the following general formula 1, or to its pharmaceutically acceptable salt, in which R1, R2, R3, X1, X2, X3, X4 and A are determined in the invention formula.
EFFECT: invention relates to an inhibitor of collagen production, a medication for treating diseases, associated with the excessive production of collagen, containing N-acylanthranilic acid derivative Formula 1.
SUBSTANCE: invention relates to nutritive therapy and is intended for treatment and/or prevention of delayed recall function impairment in subjects who have 24-26 points by Mini-mental State Examination (MMSE). Claimed is application of composition for obtaining product for enteral introduction. Composition contains uridine or uridine phosphate, docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA), phospholipids, choline, vitamin E, vitamin C, selenium, vitamin B12, vitamin B6 and folic acid.
EFFECT: claimed invention provides improvement of memory, in particular, delayed recall function, in patients with 24-26 points by MMSE.
5 cl, 1 tbl, 2 ex
SUBSTANCE: first, Fraxiparine is inhaled for 5-10 minutes. A dialysis solution for peritoneal dialysis containing extranyl is administered into the abdominal cavity 1-1.5 hours later through a catheter. The solution additionally contains: albumin in the concentration of 35-40 g/l, heparin in the concentration of 500-750 Unit/l and papaverine in the concentration of 50-100 mg/l. Every 6-8 hours after the beginning of exposure of the dialysis solution in the abdominal cavity, the Fraxiparine inhalations are repeated. The time of a single exposure of the dialysis solution in the abdominal cavity makes 12-18 hours.
EFFECT: method provides effective body detoxification in the given category of patients by providing a high toxin clearance owing to a continuous high osmotic concentration of the solution and the dilatation of pre-capillary peritoneal arterioles, prevented inspissation of the albumin solution to the colloidal state and its inactivation that reduces a rate of the dialysis solution exchanges.